We are live on ! Find out more
NVO

Novo Nordisk

463 hedge funds and large institutions have $5.53B invested in Novo Nordisk in 2017 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 170 increasing their positions, 157 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more repeat investments, than reductions

Existing positions increased: 170 | Existing positions reduced: 157

0.53% more ownership

Funds ownership: 15.48%16.02% (+0.53%)

0% more funds holding in top 10

Funds holding in top 10: 88 (0)

1% less capital invested

Capital invested by funds: $5.6B → $5.53B (-$71.3M)

4% less funds holding

Funds holding: 482463 (-19)

20% less first-time investments, than exits

New positions opened: 49 | Existing positions closed: 61

42% less call options, than puts

Call options by funds: $11.3M | Put options by funds: $19.3M

Holders
463
Holders Change
-19
Holders Change %
-3.94%
% of All Funds
11.53%
Holding in Top 10
8
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.2%
New
49
Increased
170
Reduced
157
Closed
61
Calls
$11.3M
Puts
$19.3M
Net Calls
-$8M
Net Calls Change
+$10.8M
Name Holding Trade Value Shares
Change
Change in
Stake
BL
176
BFSG LLC
California
$1.5M +$1.52M +87,528 New
TD Asset Management
177
TD Asset Management
Ontario, Canada
$1.47M +$228K +13,104 +18%
AAM
178
Azzad Asset Management
Virginia
$1.47M +$721K +41,412 +94%
Cambridge Investment Research Advisors
179
Cambridge Investment Research Advisors
Iowa
$1.46M +$296K +16,986 +25%
ARTA
180
A.R.T. Advisors
New York
$1.41M +$1.43M +82,400 New
ECM
181
EagleClaw Capital Management
Massachusetts
$1.4M +$10.4K +600 +0.7%
OAM
182
Oppenheimer Asset Management
New York
$1.4M +$1.42M +81,612 New
Creative Planning
183
Creative Planning
Kansas
$1.39M +$548K +31,492 +63%
AIA
184
Allegis Investment Advisors
Idaho
$1.38M +$186K +10,698 +15%
DLA
185
Douglas Lane & Associates
New York
$1.38M -$983K -56,456 -41%
SI
186
SII Investments
Wisconsin
$1.36M -$49.5K -2,844 -3%
BF
187
BOK Financial
Oklahoma
$1.33M +$19.2K +1,102 +1%
RCG
188
Ruane, Cunniff & Goldfarb
New York
$1.33M -$171K -9,834 -11%
NFGCM
189
Norman Fields Gottscho Capital Management
New York
$1.3M +$111K +6,400 +9%
GC
190
Guggenheim Capital
Illinois
$1.29M +$81.7K +4,690 +7%
AP
191
Atwood & Palmer
Missouri
$1.28M -$5.71M -327,852 -81%
NPF
192
Norris Perne & French
Michigan
$1.22M
SI
193
Stephens Inc
Arkansas
$1.2M +$737K +42,306 +154%
Skandinaviska Enskilda Banken (SEB)
194
Skandinaviska Enskilda Banken (SEB)
Sweden
$1.19M
NEI
195
Northwest & Ethical Investments
Ontario, Canada
$1.17M +$1.19M +68,320 New
CSM
196
CAMG Solamere Management
North Carolina
$1.14M -$14.5K -830 -1%
Bessemer Group
197
Bessemer Group
New Jersey
$1.14M -$33.3K -1,914 -3%
HGI
198
Hansberger Growth Investors
Wisconsin
$1.12M +$219K +12,556 +24%
Mariner
199
Mariner
Kansas
$1.12M +$182K +10,428 +19%
BCAM
200
Boston Common Asset Management
Massachusetts
$1.11M +$1.12M +64,540 New

NVO Hedge Fund Activity: Q1 2017 in Review

463 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2017, worth a combined $5.53B — down 1.3% from $5.6B a quarter earlier.

Sellers outnumbered buyers: 61 funds closed out of NVO and 49 opened new positions — a net loss of 12 holders — while 157 trimmed existing stakes and 170 added.

The largest buyer was State Street, adding an estimated $194M. The largest seller was Capital International Investors, cutting an estimated $79.1M.

  • 463 institutional investors held Novo Nordisk (NVO) as of Q1 2017, down from 482 in Q4 2016.
  • Funds reported $5.53B of Novo Nordisk stock for Q1 2017, down 1.3% quarter-over-quarter.
  • 49 funds opened new Novo Nordisk positions in Q1 2017 and 61 closed out, a net change of -12 holders.
  • The largest Novo Nordisk buyer in Q1 2017 was State Street, an estimated $194M added.
  • The largest Novo Nordisk seller in Q1 2017 was Capital International Investors, an estimated $79.1M sold.

Based on aggregated 13F filings for Q1 2017.